Nugmanova, D.
Feshchenko, Y.
Iashyna, L.
Polianska, M.
Malynovska, K.
Stafeyeva, I.
Makarova, J. http://orcid.org/0000-0002-1102-7618
Vasylyev, A.
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 13 April 2020
Accepted: 13 May 2021
First Online: 7 June 2021
Declarations
:
: The study was reviewed and approved by Independent Ethic Committee in Kazakhstan (Central Commission for Ethics at the Ministry of Health of the Republic of Kazakhstan) and by Local Ethic Committees in Kazakhstan, Azerbaijan and Ukraine (Ethic Committee at Semey State Medical University, Almaty, Kazakhstan; Ethic Committee at Scientific Research Institute of Lung Diseases in Baku, Azerbaijan; Commission for Ethics at National Institute of Phthisiology and Pulmonology F.G. Yanovsky of NAMS, Kiev, Ukraine; Commission for Ethics at Center for Primary Health Care #2 of Shevchenko District, Kiev, Ukraine), according to the local legal requirements. Written informed consent was obtained from each participant before any procedures or data collection related to the study.
: Not applicable.
: The study was sponsored by GlaxoSmithKline (GSK) marketing a number of treatments for COPD, Allergic Rhinitis, and Asthma. D. N., Y. F., L. I., M. P., I. S. report grants from GlaxoSmithKline, during the conduct of the study; personal fees from GlaxoSmithKline, outside the submitted work. K. M.a, J. M., and A. V. are GSK employees and shareholders.